Congressman Brett Guthrie and Congressman Buddy Carter have announced a hearing titled “Made in America: Strengthening Domestic Manufacturing and the Health Care Supply Chain.” The hearing is set to address efforts to onshore U.S.-based manufacturing, bolster the domestic supply chain, and strengthen national security interests.
“We have long been champions of policies that support efforts to onshore U.S.-based manufacturing and bolster our domestic supply chain, while, at the same time, strengthening our national security interests and economic goals,” said Chairmen Guthrie and Carter. They emphasized the importance of reducing America’s reliance on other nations for essential medications and health care products.
The Subcommittee on Health will conduct this hearing on June 11, 2025, at 10:00 AM ET in the Rayburn House Office Building. The event will be open to the public and press, with a livestream available online.
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), testified before the subcommittee. His testimony highlighted challenges in domestic generic drug manufacturing, such as global dependence on foreign active pharmaceutical ingredients (APIs), financial barriers due to lack of incentives like those in the CHIPS Act, reimbursement issues affecting generic drug prices, labor shortages in specialized pharmaceutical jobs, regulatory delays by the FDA, and gaps in biosimilar competition.
Murphy proposed solutions including financial incentives like guaranteed government purchases of essential medicines and tax credits for domestic API production. He also suggested expanding the Strategic National Stockpile to include APIs and essential medicines, investing in domestic API production hubs, streamlining FDA approvals, accelerating biosimilar approvals, ending policies favoring brand drugs over generics, and rolling back Medicaid inflation penalties.
Murphy concluded by stressing that rebuilding domestic pharmaceutical manufacturing requires long-term commitment from both government and industry. He noted that generics account for 90% of U.S. prescriptions but only 13% of drug spending.
Information from this article can be found here.
